Successful treatment with brigatinib in a patient with ALK-rearranged lung adenocarcinoma who developed crizotinib-induced interstitial lung disease

Lung Cancer. 2018 May:119:99-102. doi: 10.1016/j.lungcan.2018.03.014. Epub 2018 Mar 17.

Abstract

We present a 45-year-old patient diagnosed with anaplastic lymphoma kinase (ALK)-rearranged metastatic lung cancer who developed grade 4 interstitial lung disease (ILD) while on crizotinib treatment and was lately treated with brigatinib with no reappearance of ILD. To our knowledge, this is the first case report of successful treatment with brigatinib after crizotinib-induced ILD. Even though ILD secondary to brigatinib has been reported in clinical trials, no pulmonary toxicity has been seen in our patient, suggesting no crosslink lung toxicity between crizotinib and brigatinib.

Keywords: ALK positive; Interstitial lung disease; Lung adenocarcinoma; Lung toxicity.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Anaplastic Lymphoma Kinase / antagonists & inhibitors
  • Anaplastic Lymphoma Kinase / genetics
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Crizotinib / adverse effects*
  • Crizotinib / therapeutic use
  • Drug Substitution
  • Female
  • Gene Rearrangement
  • Humans
  • Lung Diseases, Interstitial / etiology
  • Lung Diseases, Interstitial / prevention & control*
  • Lung Neoplasms / drug therapy*
  • Middle Aged
  • Neoplasm Metastasis
  • Oncogene Proteins, Fusion / genetics
  • Organophosphorus Compounds / therapeutic use*
  • Pyrimidines / therapeutic use*
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Oncogene Proteins, Fusion
  • Organophosphorus Compounds
  • Pyrimidines
  • Crizotinib
  • ALK protein, human
  • Anaplastic Lymphoma Kinase
  • brigatinib